LEO Pharma’s Post

On this World Atopic Eczema Day, LEO Pharma shines a spotlight on atopic dermatitis (AD) - the most common form of eczema that affects millions of people across the globe. This chronic inflammatory skin condition not only causes physical discomfort with symptoms such as itch and pain, but also impacts the quality of life for patients, their families and caregivers. With AD often persisting into and sometimes beginning in adulthood, the condition results in a lifetime patient burden that is one of the largest among diseases worldwide. At LEO Pharma, we are driven to innovate to address such patient needs and strive to make a fundamental difference for those living with skin conditions. #LEOPharma #DermatologyBeyondTheSkin #AtopicEczemaDay

On this World Atopic Eczema Day, LEO Pharma shines a spotlight on atopic dermatitis (AD) - the most common form of eczema that affects millions of people across the globe. This chronic inflammatory skin condition not only causes physical discomfort with symptoms such as itch and pain, but also impacts the quality of life for patients, their families and caregivers. With AD often persisting into and sometimes beginning in adulthood, the condition results in a lifetime patient burden that is one of the largest among diseases worldwide. At LEO Pharma, we are driven to innovate to address such patient needs and strive to make a fundamental difference for those living with skin conditions. #LEOPharma #DermatologyBeyondTheSkin #AtopicEczemaDay

Komal Nandure and I are excited to highlight our latest insights into the innovative advancements in psoriasis treatment!" Did you know that new treatments for psoriasis are changing the way we manage this challenging skin condition? Psoriasis affects millions of people worldwide, often leading to discomfort and a reduced quality of life. As a healthcare professional, staying updated on the latest treatment options is crucial to improving patient outcomes. In our latest clinical review, we explore the advancements in both topical and systemic treatments for psoriasis. From new topical formulations to cutting-edge biologics and JAK inhibitors, this article dives into the most recent innovations, their mechanisms, and their clinical benefits. #Psoriasis #Dermatology #Healthcare #ClinicalReview #InnovativeTreatments

#Psoriasis affects 125 million people worldwide. It’s more than a skin condition—it can impact every aspect of life, bringing both physical discomfort and emotional strain. 🤝 This #WorldPsoriasisDay, we’re stepping up to support those living with plaque psoriasis, which accounts for 80-90% of cases. 📍 At Scinai Immunotherapeutics Ltd., we are dedicated to transforming psoriasis care. Our drug development program focuses on a targeted therapy specifically for mild to moderate plaque psoriasis. Leveraging single-domain antibodies (sdAbs), including our anti-IL-17A/F sdAb, we are advancing a locally administered biologic that combines high potency and convenience with a safer profile than current treatments. 👉 Join us in raising awareness and supporting those affected by psoriasis. Together, we can make a difference for millions. 🌐 Visit Scinai.com to learn more #InnovativeResearch #Healthcare #Biotechnology #Dermatology #WorldPsoriasisDay24

Check out the NACE Webcast: Atopic Dermatitis: Evaluation and Targeted Management. Atopic dermatitis (AD) is a chronic relapsing and remitting inflammatory skin disease that commonly presents in childhood. It is characterized primarily by scaly, pruritic, erythematous lesions located on flexural surfaces. The itch that accompanies AD has a significant impact on patients’ quality of life, with the most prominent impact being on sleep quality. Fortunately, a new understanding of its underlying pathophysiology has brought about a variety of effective treatment options for patients suffering from AD, from topical agents to biologics and oral Janus kinase (JAK) inhibitors. In this webcast, Mona Shahriari, MD, FAAD, will share her valuable insights on differential diagnosis, treatment goals, and individualizing treatment plans. Click here to start the course: https://bit.ly/3WdObsm #NACE #Dermatology #Webcast

𝐏𝐨𝐯𝐨𝐫𝐜𝐢𝐭𝐢𝐧𝐢𝐛 𝐒𝐡𝐨𝐰𝐬 𝐏𝐫𝐨𝐦𝐢𝐬𝐞 𝐢𝐧 𝐏𝐫𝐮𝐫𝐢𝐠𝐨 𝐍𝐨𝐝𝐮𝐥𝐚𝐫𝐢𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 Exciting news from Incyte Incyte at the AAD Annual Meeting! Results from a Phase 2 study of povorcitinib in prurigo nodularis (PN) patients were presented. Povorcitinib showed significant improvement in itch relief compared to placebo, with promising results in skin clearance. Dr. Kurt Brown of Incyte highlights the importance of addressing the unmet need in PN treatment. PN, characterized by itchy bumps called nodules, severely impacts patients' daily lives. The study's primary endpoint, a ≥4-point improvement in itch Numerical Rating Scale (NRS4) score, was achieved by significantly more patients receiving povorcitinib across all dosing groups compared to placebo. Dr. Martin Metz sees povorcitinib as a potential breakthrough for patients. Breaking the itch-scratch cycle is crucial in PN treatment, and these results offer hope for improved management. Povorcitinib demonstrated efficacy in itch resolution after just four weeks of treatment, indicating its potential as a novel treatment option. The study also met secondary endpoints, with a notable percentage of patients achieving Investigator’s Global Assessment Treatment Success (IGA-TS) scores and combined itch NRS4 and IGA-TS scores at Week 16. Povorcitinib was generally well-tolerated, with a safety profile consistent with previous data. These findings present a significant advancement in PN treatment, addressing the challenging symptoms and providing hope for patients worldwide. #PrurigoNodularis #SkinHealth #Dermatology #AAD2024 #HealthcareInnovation #ClinicalTrials #MedicalResearch #Incyte #Povorcitinib #SkinCare #ItchRelief #PatientCare

💊 𝗔𝗻𝘁𝗶𝗵𝘆𝗽𝗲𝗿𝘁𝗲𝗻𝘀𝗶𝘃𝗲 𝗠𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗔𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗲𝗱 𝘄𝗶𝘁𝗵 𝗘𝗰𝘇𝗲𝗺𝗮𝘁𝗼𝘂𝘀 𝗗𝗲𝗿𝗺𝗮𝘁𝗶𝘁𝗶𝘀 𝗶𝗻 𝗢𝗹𝗱𝗲𝗿 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀 👵👴 📈 Rates of physician-diagnosed eczema are rising among older adults, but the underlying causes and best treatments are still unclear. Preliminary data suggest antihypertensive medications may play a role in eczematous dermatitis. However, there's limited data on how many cases are attributed to these drugs. 🔬 A recent longitudinal cohort study of 1,561,358 older adults (mean age 67, 54% female) found a 29% increased risk of eczematous dermatitis with antihypertensive drugs over a median follow-up of 6 years. Key findings include: 💊 Diuretics: HR 1.21 💊 Calcium Channel Blockers: HR 1.16 💊 ACE Inhibitors: HR 1.02 💊 β-blockers: HR 1.04 🩺 The overall prevalence of eczematous dermatitis was 6.7%. These results suggest a small but notable increase in eczema rates among those using antihypertensive medications. Understanding this association can help clinicians better manage eczema in older patients. More research is needed to explore the underlying mechanisms. 🧬 #Healthcare #Dermatology #Cardiology #MedicalResearch #Eczema #AntihypertensiveDrugs #Pharmacology 💊📊🔬

In recognition of #MelanomaAwarenessMonth, AMLo Biosciences are sharing (to US-only audience) a patient case study demonstrating the clinical utility of their #AMBLor technology that accurately stratifies early-stage, low-risk melanomas. https://lnkd.in/eehgYpVY AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers

Sharayu Kachare and I are excited to highlight our latest insights into the innovative advancements in psoriasis treatment!" Did you know that new treatments for psoriasis are changing the way we manage this challenging skin condition? Psoriasis affects millions of people worldwide, often leading to discomfort and a reduced quality of life. As a healthcare professional, staying updated on the latest treatment options is crucial to improving patient outcomes. In our latest clinical review, we explore the advancements in both topical and systemic treatments for psoriasis. From new topical formulations to cutting-edge biologics and JAK inhibitors, this article dives into the most recent innovations, their mechanisms, and their clinical benefits. #Psoriasis #Dermatology #Healthcare #ClinicalReview #InnovativeTreatments

🚀 New Research Article Alert! I’m thrilled to share our latest findings! Our retrospective study compared the effectiveness and complication risks of distal corporoglanular shunt procedures with and without the Burnett “snake” maneuver in treating ischemic priapism (IP). Key findings: • The Burnett “snake” maneuver significantly improved priapism resolution rates and reduced recurrence. • No additional complications or loss of erectile function were observed. 🔗 Read more here #Research #IschemicPriapism #Surgery